SCHEMBL16772525

SCHEMBL16772525

Cc1ccc(-c2nc(SCC(=O)O)[nH]c(=O)c2C#N)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 4/20 0.67
▸ KMT2A Q03164 4/20 0.67
▸ POLB P06746 3/20 0.67
▸ TNF P01375 1/20 0.67
▸ PLA2G1B P04054 1/20 0.67
▸ NOD2 Q9HC29 1/20 0.67
▸ NOD1 Q9Y239 1/20 0.67
▸ ATG4B Q9Y4P1 1/20 0.67
▸ CA12 O43570 2/20 0.64
▸ CA1 P00915 2/20 0.64
▸ CA2 P00918 2/20 0.64
▸ CA9 Q16790 2/20 0.64
▸ CXCR2 P25025 1/20 0.63
▸ ALDH1A1 P00352 3/20 0.62
▸ HPGD P15428 3/20 0.62
▸ MAPT P10636 2/20 0.62
▸ LDHA P00338 4/20 0.60
▸ CYP2C9 P11712 1/20 0.59
▸ CYP2C19 P33261 1/20 0.59
▸ ACMSD Q8TDX5 3/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16772397 0.99 MEN1 (0.66) MEN1KMT2APOLBTNFPLA2G1B
SCHEMBL16772467 0.89 MEN1 (0.72) MEN1KMT2APOLBTNFPLA2G1B
SCHEMBL16775313 0.85 CA12 (0.66) MEN1KMT2APOLBTNFNOD2
SCHEMBL16775312 0.84 CA12 (0.65) MEN1KMT2APOLBTNFNOD2
SCHEMBL20468620 0.83 MEN1 (0.89) MEN1KMT2APOLBTNFPLA2G1B
SCHEMBL23850319 0.77 KMT2A (0.82) MEN1KMT2APOLBALDH1A1HPGD
SCHEMBL20099425 0.75 ACMSD (0.76) MEN1KMT2APOLBTNFPLA2G1B
SCHEMBL17550084 0.75 ACMSD (1.00) MEN1KMT2APOLBTNFPLA2G1B
SCHEMBL17553768 0.74 MEN1 (0.68) MEN1KMT2APOLBTNFPLA2G1B
SCHEMBL16775286 0.74 ACMSD (0.95) MEN1KMT2APOLBTNFPLA2G1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180222880-A1 SecA INHIBITORS AND METHODS OF MAKING AND USING THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2018-08-09 — — US disclosed
US-9957247-B2 SecA inhibitors and methods of making and using thereof GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2018-05-01 — — US disclosed
US-20150152077-A1 SecA Inhibitors and Methods of Making and Using Thereof NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-06-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180222880-A1 SecA INHIBITORS AND METHODS OF MAKING AND USING THEREOF SEC61B, SEC61A1, SEC23A MEN1 2848/4885KMT2A 4137/4885POLB 2638/4885
US-20150152077-A1 SecA Inhibitors and Methods of Making and Using Thereof SEC61B, SEC61A1, SEC23A MEN1 2848/4885KMT2A 4137/4885POLB 2638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback